Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of AggressiveCancers
CDK4/6/9i might represent a new frontier in cancer treatment to overcome the limitations of CDK4/6i and CDK9i for the treatment of cancers, including aggressive cancers with high unmet needs.
Authors
- Davide De Forni (ORCID: https://orcid.org/0009-0002-2555-1397)
- P. G. Petronini
- Franco Lori (ORCID: https://orcid.org/0000-0002-5928-172X)
- Maricla Galetti (ORCID: https://orcid.org/0000-0002-8061-8649)
- Lisette Lagacé
- Barbara Poddesu
- Giulia Cugia
- Mara Bonelli (ORCID: https://orcid.org/0000-0001-5728-7899)
- James G. Chafouleas
Institutions
- University of Parma (IT)
- University of Sassari (IT)
- Istituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro (IT)
- Instituto Nacional de las Mujeres (MX)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2024-09-03
- DOI
- https://doi.org/10.2174/0109298673298434240821101457
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00